Table 1.
Demographic, diagnosis, and treatment data for 27 patients with Wilms’ tumor
| Pat. No. | Age (years) | Sex | Tumor histology & site | Stage at dx | Patient scan # & ind | PET finding | SUVmax | CT finding |
|---|---|---|---|---|---|---|---|---|
| 1 | 3 | M | FAVORAB, right | 1 | 1 Recur (rule out) | NED | NA | 18 mm focus in right lower abdomen (possible mesenteric lymph node) |
| 2 | 2 | M | FAVORAB, right | 1 | 1 Recur (rule out) | NED | NA | 6 mm portocaval nodes |
| 3 | 5 | F | UN-DA, right | 2 | 1 Recur | NED | NA | Left lung focus (<4 mm) |
| 4 | 9 | F | FAVORAB, right | 2 | 1 Recur | 3 foci in lung | 3.1 | At least 7 foci measurable maximum size 20 mm |
| 2 Recur | Marked decreased in lung uptake | 2.2 | Maximum size 13 mm | |||||
| 3 Recur | Minimal uptake of lung foci | 1.3 | Size unchanged 13 mm | |||||
| 4 Recur | No change | 1.3 | Size unchanged 13 mm | |||||
| 5 Recur | No change | No uptake | Size decreased 11 mm | |||||
| 6 Recur | PD after RFA: increased size of 2 lung foci | 2.7 | Maximum size 32 mm | |||||
| 7 Recur | Right upper lung focus (post-RFA) | 1.1 | Maximum size 5 mm | |||||
| 8 Recur | No interval progression of disease | 1.4 | Maximum size 16 mm | |||||
| 9 RFA response | Variable uptakes of lung foci | 5.9 | Maximum size 25 mm | |||||
| 5 | 4 | F | NOS, left | 2 | 1 Recur | NED | NA | NED |
| 6 | 4 | M | FAVORAB, left | 2 | 1 Recur | Left lower lung focus | 1.8 | 10 mm |
| 7 | 10 | F | NS, left | 2 | 1 Recur | NED | NA | Stable liver foci |
| 2 Recur | NED | NA | Increased size of liver foci, later became stable | |||||
| 3 Recur | Left liver foci | 4.9 | 16 mm and 12 mm liver foci | |||||
| 4 Recur | NED | NA | 10 mm max. liver focus | |||||
| 5 Recur | NED | NA | NED | |||||
| 6 Recur | NED | NA | No study | |||||
| 7 Recur | NED | NA | No study | |||||
| 8 Recur | NED | NA | No study | |||||
| 9 Recur | 2 new foci in liver and pancreas | Liver 4 and pancreas 7.6 | 46 mm focus in pancreatic tail; 9 mm liver foci | |||||
| 8 | 23 | M | FAVORAB, right | 3 | 1 Recur | Right liver focus | 9.1 | 98 mm |
| 9 | 7 | M | FAVORAB, left | 3 | 1 Recur | Right upper mediastinal focus | 4.3 | 33 mm |
| 10 | 9 | M | FAVORAB, left | 3 | 1 Recur (prior) | NED | NA | NED |
| 2 Recur (prior) | NED | NA | NED | |||||
| 3 Recur (prior) | NED | NA | NED | |||||
| 4 Recur (prior) | NED | NA | NED | |||||
| 5 Recur (prior) | NED | NA | NED | |||||
| 6 Recur (prior) | NED | NA | NED | |||||
| 7 Recur (prior) | NED | NA | NED | |||||
| Mediastinal focus | Partial dose extravasation | 10 mm | ||||||
| Right hilar focus | 11 mm | |||||||
| 11 | 2 | F | NS, right | 3 | 1 Refractory | Multiple foci in abdomen, liver and supraclavicular area | Liver 8.3; abdomen 7.2 and supraclavicular 5.2 | 44 mm liver focus; 55 mm abdominal focus and 25 mm supraclavicular focus |
| 12 | 7 | M | FAVORAB, left | 3 | 1 Recur | Right para-aortic and L2 vertebral body | 3.9 | 27 mm soft tissue mass at L2 level and adjacent sclerotic lesion at L2 |
| Post-midthoracic paraspinal mass | 3.2 | 25 mm | ||||||
| 2 Resp | NED | Sclerosis at L2 | ||||||
| 13 | 6 | F | ANAPLAS, right | 3 | 1 Recur | Multiple soft tissue foci including dome liver, tip of the spleen, right renal bed, para-aortic, mesenteric and pelvic | Unavailable | Not recorded |
| 14 | 4 | F | FAVORAB, extrarenal | 3 | 1 End Rx | Supra bladder cystic focus (residual tumor) | Could not be assessed on outside study | |
| 15 | 3 | M | FAVORAB, right | 4 | 1 Resp | Multiple right lung foci | 2.2 | 12 mm (max. size) |
| Left lobe liver focus | 3.4 | 13 mm | ||||||
| 2 Resp | Lung foci almost resolved | NA | Very small lung focus (<2 mm) | |||||
| Liver focus resolved | NA | Liver focus resolved | ||||||
| 3 Recur | NED | NA | ||||||
| 4 Recur | NED | NA | ||||||
| 5 Recur | Right lung(new focus) | 1.7 | 10 mm | |||||
| 16 | 7 | F | FAVORAB, left | 4 | 1 Base | Lung: multiple foci | 5.1–8.6 | Largest 30 mm |
| Multiple liver foci | 6.3–9.0 | 10–30 mm | ||||||
| Left renal focus | 8.1 | 95 mm | ||||||
| 2 Resp | NED | NA | Very small lung foci | |||||
| 17 | 11 | F | FAVORAB, right | 4 | 1 Recur | Bilateral small lung foci | NA | Small lung foci <10 mm |
| Para-aortic focus | 7.5 | 15 mm | ||||||
| Liver 2 foci | 5.6 | 10 mm, 12 mm | ||||||
| Retroperitoneal 2 foci | 8.9 | 13 mm, 48 mm | ||||||
| Pancreatic foci | 8.6 | 35 mm | ||||||
| Left tibial focus | 5.9 | 30 mm | ||||||
| 18 | 16 | M | FAVORAB, left | 4 | 1 Recur | Right hilar focus | 2.7 | 15 mm |
| Right lung focus | 14.5 | 100 mm | ||||||
| Right liver focus | 13.5 | 90 mm | ||||||
| Left liver focus | 11.5 | 40 mm | ||||||
| 2 Recur | Right hilar focus | 3.5 | 30 mm | |||||
| Right lung focus | 10.1 | 110 mm | ||||||
| Right lobe liver focus | 11.1 | 72 mm | ||||||
| Left lobe liver focus | 9.6 | 53 mm | ||||||
| 19 | 13 | M | ANAPLAS, right | 4 | 1 Base (after surgery) | Retroperitoneal focus | 6.4 | 15 mm |
| No pulmonary abnormalities | Bilateral lung foci <5 mm | |||||||
| 20 | 9 | F | NS, right & site | 4 | 1 Recur (prior) | NED | NA | Negative |
| 21 | 12 | F | FAVORAB, left 7 mm lung focus |
4 | 1 | (persistence) | NED | NA |
| 8 mm lung focus | 2 | (persistence) | NED | NA | ||||
| 22 | 4 | F | FAVORAB, left | 4 | 1 Recur | 4 foci in right lung | Not accurate due to residual activity in injection line | 4 foci (size: 16–20 mm) |
| NED | NA | RML focus (<5 mm) | ||||||
| 23 | 5 | M | FAVORAB, left | 4 | 1 Recur | Right lung focus | Not valid due to partial dose extravasation | 20 mm |
| Mediastinal focus | 10 mm | |||||||
| Right hilar focus | 11 mm | |||||||
| 24 | 12 | F | FAVORAB, left | 4 | 1 Resp | Active left lower lung with pleural focus consistent with metastatic disease | 9.2 | 43 mm |
| 25 | 2 | M | UN-DA, bilateral | 5 | 1 Recur | NED | NA | CT-guided needle biopsy at T11 level: negative for bone metastasis |
| 26 | 4 | M | NOS, bilateral | 5 | 1 Recur | NED | NA | NED |
| 27 | 8 | F | FAVORAB, bilateral | 5 | 1 Resp | Liver focus | 10.9 | 48 mm |
| Right neck focus | 2.7 | 14 mm | ||||||
| Left neck focus | 2.4 | 7 mm | ||||||
| Left Internal mammary focus | 2.4 | 11 mm | ||||||
| 2 Resp | NED | NA | 24 mm Liver focus |
Pat. patient, dx diagnosis, ind indication, PET positron emission tomography, SUV standardized uptake value, CT computed tomography, Recur recurrent disease, RFA radiofrequency ablation, End RX end-of-treatment assessment, Resp treatment response assessment, Base baseline (pretreatment) assessment, NED no evidence of disease, RML right middle lobe, PD progressive disease, NOS not otherwise specified, UN-DA unfavorable histology diffuse anaplasia, FAVORAB favorable histology, ANAPLAS anaplastic histology, NS not stated, NA not applicable